Hememics Biotechnologies, a company specializing in the development of a groundbreaking handheld biosensor platform, has successfully closed a $2 million Seed 2 financing round. The round included participation from a strategic investor, existing investors, and Maryland Technology Development Corporation (TEDCO).
Hememics’ handheld biosensor platform is a first-of-its-kind solution that enables simultaneous testing of antibodies, antigens, and molecular targets. Over the past nine months, the company has conducted more than 100,000 biosensor experiments, yielding highly favorable results. With the new funding, Hememics aims to finalize the design, obtain third-party validation, and secure early commercial customers.
John Warden, Jr., CEO and Co-founder of Hememics Biotechnologies, expressed pride in the company’s accomplishments despite limited resources. The funding will provide the necessary resources to further enhance the platform and drive commercial adoption.
Dr. David Ho, Co-founder, President, and CSO, highlighted the significance of the patented desiccation solution in integrating biologics with graphene-based electronics. This crucial development took seven years, and an additional four years were dedicated to refining the platform. The new funding will support the company’s growth trajectory and facilitate early commercial success.
Hememics Biotechnologies utilizes graphene-based sensors and patented bio preservatives to deliver laboratory-quality testing performance in a handheld format. The company’s portable and cost-effective platform features a user-friendly reader paired with a single-use biochip containing 32 sensors. Each sensor can be programmed individually to detect molecular, antigen, and antibody targets. By placing a lab in the user’s hand, Hememics simplifies workflows and provides results within minutes, enabling timely decision-making in various settings such as farms, emergency rooms, and battlefields.
Hememics Biotechnologies, Inc. is positioned to accelerate its progress and expand the reach of its innovative biosensor platform with the recent seed funding round.
